Online citations, reference lists, and bibliographies.
← Back to Search

Clinical And Pathological Features Of Three-year Survivors Of Malignant Pleural Mesothelioma Following Extrapleural Pneumonectomy.

D. Sugarbaker, A. Wolf, L. Chirieac, J. Godleski, T. R. Tilleman, M. Jaklitsch, R. Bueno, W. Richards
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE Surgery-based multimodality therapy is associated with long-term survival in a significant number of pleural mesothelioma patients. We explored factors associated with 3-year survival in patients with malignant pleural mesothelioma, who underwent extrapleural pneumonectomy, to help refine patient selection criteria for surgery and other therapies. METHODS With Institutional Review Board approval, we reviewed records in the International Mesothelioma Program Patient Data Registry to identify all patients, who underwent extrapleural pneumonectomy for malignant pleural mesothelioma between 1 January 1988 and 31 May 2007. Vital status as of 31 May 2010 was confirmed. Fisher's exact test was used to compare dichotomous variables for patients who survived at least 3 years with those who did not. Kaplan-Meier analysis was used to estimate the cumulative survival probability for all 3-year survivors. RESULTS Among 636 patients who underwent extrapleural pneumonectomy, 117 (18%) survived at least 3 years following surgery, including 26 remaining alive and four lost to follow-up. Of the 3-year survivors, 39 (33%) were female, 61 (52%) had left-sided disease, and the median age was 56 years (range 27-77). Relatively more 3-year survivors were younger than, or at the median age (p=0.0005), or female (p=0.0007), had epithelial tumor histology (p<0.0001) and/or had normal white blood cell count (p=0.0001), hemoglobin (p<0.0001), or platelet count (p<0.0001) preoperatively. The median survival of the 117 patients who survived 3-years was 59 months. Among these patients, a significant association between age and survival was found only for women. CONCLUSIONS A significant proportion of patients undergoing extrapleural pneumonectomy for pleural mesothelioma experienced extended survival. Although favorable prognostic features were more common, the cohort of 3-year survivors included a substantial number of patients with late-stage disease. The longest survival (median greater than 7 years) was experienced by women under the median age of 56 years. These data support the role of macroscopic cytoreduction through extrapleural pneumonectomy in the context of multimodality therapy to extend survival for malignant pleural mesothelioma. Further efforts to treat micrometastatic disease and improve patient selection are warranted.
This paper references
Malignant pleural mesotheli
AS Tsao (2009)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Validation of the 6 th edition AJCC pancreatic cancer staging system : report from the National Cancer Database
KY Bilimoria (2007)
10.1007/S11864-000-0047-4
Malignant pleural mesothelioma
H. Kindler (2000)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1053/j.semtcvs.2009.06.008
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
R. Flores (2009)
10.1586/ers.10.35
Surgery for malignant pleural mesothelioma
D. Sugarbaker (2010)
10.1001/ARCHSURG.139.5.532
Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
S. Malaisrie (2004)
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1371/journal.pone.0010612
Second Generation Sequencing of the Mesothelioma Tumor Genome
R. Bueno (2010)
10.1200/JCO.1995.13.8.1880
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
K. Albain (1995)
10.1016/j.athoracsur.2010.04.110
Characteristics of malignant pleural mesothelioma in women.
A. Wolf (2010)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1073/pnas.0712399105
Transcriptome sequencing of malignant pleural mesothelioma tumors
D. Sugarbaker (2008)
10.1053/j.semtcvs.2009.07.002
Recent advances in mesothelioma staging.
W. Richards (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/S0360-3016(00)00736-7
Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center.
R. Komaki (2000)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1158/0008-5472.CAN-08-4523
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
10.1002/cncr.22852
Validation of the 6th edition AJCC pancreatic cancer staging system
K. Bilimoria (2007)



This paper is referenced by
10.1007/s11748-018-1027-6
Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma
D. Magouliotis (2018)
10.1093/ICVTS/IVT372.331
331PREDICTORS OF LONG-TERM SURVIVAL FOLLOWING RADICAL SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA
A. Nakas (2013)
10.1038/modpathol.2017.108
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma
M. Vivero (2018)
10.1016/j.athoracsur.2015.01.024
About Chimney Technique for Mitral Valve Replacement.
H. Çakır (2015)
10.1007/s11748-014-0389-7
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
S. Hasegawa (2014)
10.1186/s12957-015-0624-4
Effects of sex hormones on survival of peritoneal mesothelioma
Y. Huang (2015)
10.1007/978-1-4471-6404-3_50
Pleurectomy Versus Radical Pleuropneumonectomy for Malignant Pleural Mesothelioma
S. R. Carr (2014)
10.5301/tj.5000418
Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma
R. Berardi (2016)
10.1016/j.athoracsur.2014.04.040
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
E. Taioli (2014)
10.2217/LMT.15.16
Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?
A. Wolf (2015)
10.1016/j.jtcvs.2017.12.131
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
H. Batırel (2018)
10.1080/17476348.2019.1607300
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma
K. Shohdy (2019)
10.1016/j.cllc.2020.05.021
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
A. Barsky (2020)
10.1016/j.thorsurg.2016.04.003
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
A. Wolf (2016)
10.1093/ejcts/ezv403
The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.
A. Sharkey (2016)
10.1002/cncr.32416
Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma
L. Chirieac (2019)
10.6004/JNCCN.2016.0087
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
10.1093/icvts/ivs465
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
J. Lindenmann (2013)
Ki 67-BCL 2 index in prognosis of malignant peritoneal mesothelioma
K. Pillai (2013)
10.1007/978-3-319-53560-9_13
Surgery Approaches in Mesothelioma
A. Wolf (2017)
10.21037/atm.2017.03.82
Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).
H. Batırel (2017)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1016/j.soc.2020.06.002
Updates in Staging and Management of Malignant Pleural Mesothelioma.
A. Wolf (2020)
10.2143/ACB.3362
PATHOLOGIC COMPLETE REMISSION OF MALIGNANT PLEURAL MESOTHELIOMA AFTER COMBINED MODALITY TREATMENT: A CASE REPORT
K. Moubax (2013)
10.5761/atcs.oa.17-00192
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
T. Miyazaki (2018)
10.1016/j.soc.2012.12.004
Multimodality treatment of pleural mesothelioma.
David D. Shersher (2013)
10.1055/s-0035-1565246
A Surgical View of Photodynamic Therapy in Oncology: A Review.
K. Moghissi (2015)
10.1016/j.athoracsur.2014.01.050
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
L. Spaggiari (2014)
10.1016/j.athoracsur.2015.04.077
Reply: To PMID 24726598.
L. Spaggiari (2015)
10.1016/j.jtcvs.2014.01.007
WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience.
S. Qadri (2014)
Clinicopathologic indices can improve patient selection in malignant mesothelioma.
D. Sugarbaker (2012)
10.1016/j.athoracsur.2019.03.052
Disparities in Compliance with National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
Fernando Espinoza-Mercado (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar